Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corporation reported that the U.S. Food and Drug Administration approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. This expands Afrezza’s use beyond adults into the pediatric diabetes population.
The FDA also stated that the supplemental biologics license application for this pediatric indication has fulfilled the last remaining postmarketing requirement for Afrezza from its original June 27, 2014 approval. This means all originally required follow-up obligations for Afrezza have now been completed.
MannKind Corporation reports a key regulatory change and a pediatric clinical update for its inhaled insulin Afrezza. The FDA has released the company from a postmarketing requirement to run a five-year, randomized trial in 8,000-10,000 adults with type 2 diabetes to assess pulmonary malignancy risk versus standard care. The only remaining postmarketing requirement for Afrezza is a study of efficacy and safety in pediatric patients.
The FDA is reviewing a supplemental Biologics License Application for Afrezza use in children and adolescents aged 4-17 with a PDUFA target action date of May 29, 2026. MannKind is also enrolling the INHALE-1st study in youth aged 10-17 with newly diagnosed type 1 diabetes, following up to 100 participants across 10 sites for 13 weeks, with an optional 26-week extension, and expects data in late 2027.
Friedman Michael A reported acquisition or exercise transactions in this Form 4 filing.
MANNKIND CORP director Michael A. Friedman reported a grant and vesting of 82,781 restricted stock units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of MannKind common stock. The RSUs vested on May 20, 2026, but the underlying shares will only be delivered after Friedman separates from service on the MannKind board of directors. Following this award, he holds 82,781 RSUs directly.
MannKind Corporation director Ronald J. Consiglio reported equity compensation and a share purchase tied to his board service. He acquired 10,000 shares of common stock at $2.95 per share through the company’s Market Price Stock Purchase Plan, which was approved by the board on May 20, 2026.
He also received two awards of restricted stock units (RSUs) covering 16,556 and 82,781 units. Each RSU represents a contingent right to receive one share of MNKD common stock, with shares generally delivered only after separation from the board. Following these transactions, he directly holds 132,342 common shares. Footnotes note that 423,655 deferred RSUs were inadvertently included in prior reported share holdings.
Binder Steven B. reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corporation director Steven B. Binder reported receiving a grant of restricted stock units under the company’s equity compensation program. He was awarded 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.
The filing notes that these restricted stock units vested on May 20, 2026, but the underlying shares will not be delivered until Binder experiences a separation of service from MannKind’s board of directors. After this grant, he holds 82,781 restricted stock units directly, highlighting a compensation-related equity award rather than an open-market share purchase or sale.
Grancio Jennifer reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp director Jennifer Grancio reported a compensation-related equity award and updated holdings. She received a grant of 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.
The restricted stock units vested on May 20, 2026, but the underlying shares will only be delivered after her separation of service from MannKind’s board of directors. Following the reported transactions, she holds 110,701 shares of common stock directly, alongside the newly granted 82,781 restricted stock units. A footnote also clarifies that 134,114 shares representing deferred restricted stock units had been inadvertently included in prior reported common stock holdings.
MannKind Corporation director Anthony C. Hooper reported equity-based compensation in the form of restricted stock units (RSUs). On May 20, 2026, he received an award of 16,556 RSUs, each representing a contingent right to one share of MannKind common stock, which vested that day but will only be delivered after he separates from the board.
On the same date, he also received a second grant of 82,781 RSUs in lieu of his annual cash retainer as a non-employee director. This award vests immediately, with share delivery likewise deferred until his separation from board service. These are compensation-related acquisitions, not open-market purchases or sales of MannKind shares.
Shannon James Samuel reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corporation director James Samuel Shannon reported new equity awards and updated his share holdings. The filing shows he holds 36,458 shares of MannKind common stock directly. He also received two grants of restricted stock units (RSUs) tied to MannKind common stock.
One RSU grant covers 16,556 units that vested on May 20, 2026, but the underlying shares will only be delivered after he separates from service on MannKind’s board. A second grant of 82,781 RSUs was awarded in lieu of an annual cash retainer for non‑employee directors and vests immediately, with share delivery also deferred until board service ends. Each RSU represents the right to receive one share of MannKind common stock.
MANNKIND CORP Chief People & Workpl Officer Stuart A. Tross reported acquiring 33,898 shares of common stock at $2.95 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on May 20, 2026. Following this transaction, he directly owns 1,026,122 common shares.
MannKind Corp executive Dominic Marasco, President of the Endocrine Business Unit, reported an acquisition of company stock through a compensation-related plan. He received 8,474 shares of common stock at $2.95 per share under the issuer's Market Price Stock Purchase Plan, which was approved by the board on May 20, 2026. Following this award, his directly held position increased to 344,246 shares of common stock, which includes 2,343 shares acquired under the issuer's Employee Stock Purchase Plan on December 31, 2025.